Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
Sponsor: CRISPR Therapeutics AG
Summary
A Study of CTX340 in Participants with Uncontrolled Hypertension.
Official title: A Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2026-08-08
Completion Date
2029-07-01
Last Updated
2026-08-11
Healthy Volunteers
No
Conditions
Interventions
CTX340
CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.
Placebo
One of the arms in Phase 2 will be placebo.
Locations (2)
Research Site 1
Port Orange, Florida, United States
Research Site 2
Melbourne, Australia